Does anyone know why the stock fell by ~6% despite posting decent numbers?
Posts in category Value Pickr
Shankara Build Pro – Building Materials Organised Retail (11-08-2024)
Anyone attended the conference call of 9 August? If yes, please upload the key points please.
Manappuram Finance (11-08-2024)
Can someone please share the net profit from the Ahirvad result? I’m unable to open the link.
Trent — A value unlocking story from the house of TATA (11-08-2024)
Results of Q1 FY25 has further strengthen the confidence that Trent is clearly emerging as market leader in organized fashion retail. By conservative estimates Trent is expected to end the year between 18k crores to 20k crores revenues. I have compared the Sales of Top 10 listed fashion retailers( i could not get fashion retail data of Reliance)
| Company | FY 24 Sales | Growth | Q1 FY 25 | Growth | |
|---|---|---|---|---|---|
| 1 | Aditya Birla Fashion & Retail Ltd | 13996 | 12.71% | 3428 | 7.25% |
| 2 | Trent | 12375 | 50.00% | 4104 | 56.00% |
| 3 | Avenue Supermarts Ltd(Apparel & G.Merch,) | 11174 | 18.56% | 3095 | 18.57% |
| 4 | Shopper stop | 4317 | 7.32% | 1069 | 7.62% |
| 5 | V-Mart Retail Ltd | 2786 | 13.01% | 786 | 15.25% |
| 6 | Spencer’s Retail Ltd | 2345 | -4.39% | 548 | -3.83% |
| 7 | Sai Silks (Kalamandir) Ltd | 1843 | 1.63% | 267.29 | -12.25% |
| 8 | Redtape Ltd | 1374 | 25.51% | ||
| 9 | Vedant Fashions Ltd | 1368 | 93.00% | 240 | -23.04% |
| 10 | V2 Retail Ltd | 1165 | 38.84% | 415 | 57.00% |
| Above data is from Screener.in |
Manappuram Finance (11-08-2024)
What is happpening in IPO front of Asirvad? Is it going to happen or still some issues left. Anybody who has clear cut understanding of matter, please help us in understanding the matter of their ipo route through holding corporation? Why they are not demerging Asirvad and seperately listing them on exchanges?
The Anti-Portfolio (11-08-2024)
Hi Vikas! First of all huge congrats for such great investments and finally buying out the house! Really happy for you…
May I know when and why did you exit Beta Drugs completely? I believe it has great prospects in the times ahead of it.
The Anti-Portfolio (11-08-2024)
Thank you @Prdnt_investor
I should have restated the above explanation in all subsequent posting also. Apologies for the laziness! My portfolio in value-research and trendlyne.com both just reflect the IT department view on the pricing, which is not correct in my POV. But it takes extra effort to calculate and manually update the folio data.
KPI green was bought in overwhelming majority chunk in August 2022, and last buy was September 2023. So it’s one of the rare stock where the conviction lasted this long. It was easy, heard about it somewhere. Then checked KP Energy, the older listed group company was verified by @prasenjitp04, a pretty famous investor, posting here on valuepickr. Just that wind energy turned low profile and solar kicked up a storm instead in the meanwhile. In all the solar sector hype I found this very cheap also.
Tinna was identified as per running some screens, or somewhere, do not recall exactly. Then a few weeks later, luckily @sahil_vi posted some good research about this here at valuepickr. I began to know and trust more, but rejected it as not a ‘value-able’ enough find, for few weeks more. The entire chunk of the investment was bought in January 2023. Tyre recycling ESR mandate was just starting and supposed to be 100% I think by 2030. Plus they were the largest of the sector, with international reach, though European subsidiary continues to be dormant still.
Generally speaking, if at all you are still interested, since as per me these are only about 12x now. The method of picking is fast growing, bought (relatively) early. Or GARP for short, thanks to Peter Lynch.
Both were ranking about the middle in my 12-14 stock portfolio, bit closer to the top, by initial investment size. I have booked 70% of KPIGREEN because I want to explore more fast growing stocks, valuation wise. I have booked only 30% of Tinna mainly to keep folio a bit balanced, also bit pleasantly surprised by the rerating here, and just kept watching. The churn happened mainly in December 2023 when switched to promising ones like Shilchar, E2E, Ceinsys, Zen tech etc.
Keeping holding till there is enough juice left in the valuation, while minding the forward earnings (‘growth’), compared to at least better than any current ideas being evaluated. Given risk and switching costs too.
Disc: unqualified to advise, hence please do your own research.
Ranvir’s Portfolio (11-08-2024)
Hi …
No … I have no idea about how do they do it 
Regards
The Anti-Portfolio (11-08-2024)
Congratulations Vikas for your new house and a great run in the market.
A lot of YouTube influencers advocate buying a house on mortgage even if one has the money to buy it outright. This is because mortgage rates are in line with inflation while the same money in market would yield better returns in the long run. Sounds logical to me but in times of downturn can also bite us when paying emi by withdrawing monthly from market. What do you think?
Ranvir’s Portfolio (11-08-2024)
Alkem Labs –
Q1 FY 25 Concall and results highlights –
Revenues – 3031 vs 2967 cr
Gross margins @ 64 vs 59 pc ( huge expansion )
EBITDA – 608 vs 389 cr, up 56 pc ( margin @ 20 vs 13 pc !!! )
PAT – 545 vs 286 cr, up 90 pc
R&D expenses @ 125 cr, 4 pc of sales
Cash on books @ 3845 cr
Alkem’s rank in major therapeutic segments in IPM –
Anti Infectives – 01
Vit/Minerals – 02
Pain Analgesics – 03
GI – 03
Among the chronic therapies, Alkem is ranked 7th in Neuro, 15th in Anti-Diabetic and Respiratory, 20th in Derma and 26 th in Cardiac segments
Breakup of revenues –
India sales – 2022 cr, up 6 pc ( 67 pc of total sales )
International sales – 967 cr, down 4 pc
Out of this, US sales @ 641 cr, down 8 pc
RoW sales @ 326 cr, up 2 pc
Massive improvement in Gross and EBITDA margins on the back on sharper focus on profitability, favourable RM cost environment and cost control initiatives
Will continue to invest aggressively towards future growth opportunities ( basically ENZENE’s Biosimilars plant in the US which is likely to turn profitable only in FY 27. Company is spending 400-450 cr towards this facility ). These are likely to entail operational costs. Hence sticking to full yr’s EBITDA margin guidance of 18 pc for FY 25. However, if the API prices continue to remain soft and decline further, company may report higher margins
Domestic growth in Q1 is driven by volume growth of 1.5 pc, new products at 2.5 pc and price hikes of about 2 pc
US generics business is seeing price erosion in single digits
Guiding for an R&D costs at around 4.5-5 pc of sales for FY 25
Looking at single digit growth from US mkt in FY 25. Will be launching 3-4 products and filing for 8-10 new products for US in FY 25
Expecting the growth to pick up in a significant way in the European + EMs. These mkts are showing encouraging signs and company is hopeful of growing briskly and more profitably ( vs US ) here. These Mkts are a big focus area for the company. Q1 was weak because of some supply chain issues which now stand resolved. Guiding for a mid teens kind of growth from non-US International business for next 2-3 yrs. Blended margins in these international mkts are > US and < India
Trade generics contribute to around 20 pc of company’s India business
Tax rate guidance for FY 25 @ 11-13 pc
Share of Chronic therapies in company’s India business @ 19 pc. 81 pc is acute business
Medical devices, OTC products – are two business areas where the company is working hard. Will share updates with shareholders when they finally launch products in these spaces
Cash on books to be used for acquisitions / mergers etc to add value to the business
ENZENE Biosciences ( a subsidiary ), already has 07 biosimilars in the IPM. Aim to launch 05 more over the medium term. Their US facility ( under development ) will be utilised for contract manufacturing
Disc: holding, biased, not SEBI registered, not a buy/sell recommendation